NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Bioxodes

Bioxodes

Private
BelgiumHealthcare & Life Scienceshttps://bioxodes.com/

Last Round

Series B

Dec 10, 2025

Total Funding Raised

$25.25M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Bioxodes is a clinical-stage biopharmaceutical company that develops therapies to treat thrombotic and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

intracerebral hemorrhagebiotechnologyhemorrhagic strokeclinical-stage biotechdrug developmenttherapeutic candidatebiopharmaneurocritical careclinical trialsrecombinant peptidedrug discoverystroke treatmentbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bioxodes Comps

Public and private peers based on sector, stage, and business model.

Bioxodes comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Bioxodes Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 10, 2025
Series A ExtensionFeb 12, 2025
GrantNov 21, 2023
Series ANov 21, 2023
SeedNov 26, 2013
Grant
Nov 1, 2013

Key People

Founding team and executive leadership

Marc Dechamps

Chief Executive Officer

Executive Team

Bioxodes Investors

Notable investors and investment history

Bioxodes investors
InvestorRounds
Federal Holding and Investment CompanySeries A Extension
Newton BiocapitalSeries B
Life Sciences Research PartnersSeries B, Seed, Series A Extension, Series A
European Regional Development FundGrant, Seed
Financière Spin-off LuxembourgeoiseSeries B, Seed, Series A Extension, Series A
Walloon Region (Belgium)Seed, Series A
SambrinvestSeries B, Seed, Series A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 64% MoM, reaching 2.1K.

  • Apr 17, 2026

    BIOX-101 for ICH is in dialogue with regulators for pivotal trial design.

Bioxodes Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Bioxodes Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Bioxodes's valuation, stock price, and market status.

Firmographic Details

HeadquartersBelgium
Employee Range12
Year Founded2013
Last FundingDec 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.